Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
Advances and Perspectives in Diagnosis and Treatment Strategies for Bladder...
share announcement

Advances and Perspectives in Diagnosis and Treatment Strategies for Bladder Cancer

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Genitourinary Oncology".

Deadline for manuscript submissions: closed (15 August 2023) | Viewed by 7766

Special Issue Editors

Dr. Julieta Alexandra Pereira Afonso

E-Mail Website
Guest Editor
1. School of Medicine, University of Minho, 4710-057 Braga, Portugal
2. ICVS/3B's PT Government Associate Laboratory, 4710-057 Braga, Portugal
Interests: bladder cancer; chemoresistance; immunotherapy resistance; cancer metabolism; Warburg effect; monocarboxylate transporters; CD147; tumor microenvironment; cancer-associated fibroblasts
Special Issues, Collections and Topics in MDPI journals
Dr. Maria de Fátima Monginho Baltazar

E-Mail Website
Guest Editor
1. School of Medicine, University of Minho, 4710-057 Braga, Portugal
2. ICVS/3B's PT Government Associate Laboratory, 4710-057 Braga, Portugal
Interests: cancer glycolytic metabolism; new metabolic biomarkers in cancer; cancer drug resistance; drug discovery in cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bladder cancer is the tenth most commonly diagnosed malignancy and the thirteenth leading cause of cancer-related death worldwide, and its incidence is gradually increasing. Elevated rates of recurrence and progression in patients with localized disease, and resistance to classical cisplatin-based chemotherapy in patients displaying muscle-invasive and metastatic tumors, make direct and indirect costs of patient care higher than in any other type of cancer. Molecular profiling is definitively altering diagnosis, surveillance and the treatment landscape of bladder cancer. Minimally invasive diagnostic approaches are evolving, and therapeutic options for advanced disease have been expanded with immune checkpoint inhibitors, targeted therapies and antibody drug conjugates. Despite these developments, resistance to classical and novel therapeutics occurs in a considerable proportion of patients, and the challenge of unravelling the underlying mechanistic insights remains. Biomarkers for the proper identification of patients who will better respond to therapy are also being investigated, and new potential therapeutic targets will certainly arise. This Special Issue will highlight recent advances and future perspectives in diagnosis and treatment strategies for bladder cancer, from basic research to clinical applications that ultimately aim to improve diagnosis, monitoring and management of bladder cancer patients. 

You may choose our Joint Special Issue in Cancers.

Dr. Julieta Alexandra Pereira Afonso
Dr. Maria de Fátima Monginho Baltazar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bladder cancer
  • non-muscle invasive
  • muscle-invasive
  • diagnosis
  • treatment
  • resistance to treatment
  • biomarkers
  • therapeutic targets

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 500 KiB  
Article
The Impact of Variant Histology in Patients with Urothelial Carcinoma Treated with Radical Cystectomy: Can We Predict the Presence of Variant Histology?
by Nebojsa Prijovic, Miodrag Acimovic, Veljko Santric, Branko Stankovic, Predrag Nikic, Ivan Vukovic, Milan Radovanovic, Luka Kovacevic, Petar Nale and Uros Babic
Curr. Oncol. 2023, 30(10), 8841-8852; https://doi.org/10.3390/curroncol30100638 - 27 Sep 2023
Cited by 1 | Viewed by 1813
Abstract
Considering the divergent biological behaviors of certain histological subtypes of urothelial carcinoma, it would be of great importance to examine the impact of variant histology and to predict its presence in patients with bladder cancer. A single-center cohort study included 459 patients who [...] Read more.
Considering the divergent biological behaviors of certain histological subtypes of urothelial carcinoma, it would be of great importance to examine the impact of variant histology and to predict its presence in patients with bladder cancer. A single-center cohort study included 459 patients who underwent radical cystectomy for urothelial carcinoma between 2017 and 2021. Patients were followed up with until July 2022. We compared clinical, laboratory, and histopathologic characteristics and the overall survival between patients with pure urothelial carcinoma and variant histologies. Our results showed that the patients with variant histology were older and preoperatively more frequently had hydronephrosis and higher values of leukocytes and neutrophils. Also, we found a significant association between variant histology and an advanced stage of tumor disease, the presence of lymphovascular invasion, positive surgical margins, and metastases in surgically resected lymph nodes. The number of neutrophils was identified as an independent preoperative predictor of the presence of variant histology after a radical cystectomy. The overall survival of the patients with variant histology was significantly lower compared to the patients with pure urothelial carcinoma. According to our results, the presence of variant histology represents a more aggressive form of the disease. Preoperative neutrophil counts may indicate the presence of variant histology of urothelial carcinoma in patients with bladder cancer. Full article
(This article belongs to the Special Issue Advances and Perspectives in Diagnosis and Treatment Strategies for Bladder Cancer)
►▼ Show Figures

Figure 1

16 pages, 2450 KiB  
Article
Predictive Value of Inflammatory and Nutritional Indexes in the Pathology of Bladder Cancer Patients Treated with Radical Cystectomy
by Nebojsa Prijovic, Miodrag Acimovic, Veljko Santric, Branko Stankovic, Predrag Nikic, Ivan Vukovic, Ivan Soldatovic, Djordje Nale, Luka Kovacevic, Petar Nale, Adrian Marinkovic and Uros Babic
Curr. Oncol. 2023, 30(3), 2582-2597; https://doi.org/10.3390/curroncol30030197 - 21 Feb 2023
Cited by 4 | Viewed by 2522
Abstract
In recent years, the focus of numerous studies has been the predictive value of inflammatory and nutritional parameters in oncology patients. The aim of our study was to examine the relationship between the inflammatory and nutritional parameters and the histopathological characteristics of patients [...] Read more.
In recent years, the focus of numerous studies has been the predictive value of inflammatory and nutritional parameters in oncology patients. The aim of our study was to examine the relationship between the inflammatory and nutritional parameters and the histopathological characteristics of patients with bladder cancer. A retrospective study included 491 patients who underwent radical cystectomy for bladder cancer between 2017 and 2021. We calculated the preoperative values of the neutrophil-to-lymphocyte ratio (NLR), the derived neutrophil-to-lymphocyte ratio (dNLR), the systemic immune-inflammation index (SII), the systemic inflammatory response index (SIRI), the platelet-to-lymphocyte ratio (PLR), the lymphocyte-to-monocyte ratio (LMR), the prognostic nutritional index (PNI), and the geriatric nutritional risk index (GNRI). Statistically significant positive correlations were observed between NLR, dNLR, SII, SIRI, and PLR and the pathological stage of the tumor. We observed statistically significant inverse correlations for LMR, PNI, and GNRI with the tumor stage. SIRI was identified as an independent predictor of the presence of LVI. dNLR was identified as an independent predictor of positive surgical margins. GNRI was identified as an independent predictor of the presence of metastases in the lymph nodes. We noticed the predictive value of SIRI, dNLR, and GNRI in the pathology of bladder cancer patients. Full article
(This article belongs to the Special Issue Advances and Perspectives in Diagnosis and Treatment Strategies for Bladder Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 3691 KiB  
Review
Intravesical Contrast-Enhanced MRI: A Potential Tool for Bladder Cancer Surveillance and Staging
by Pradeep Tyagi, Chan-Hong Moon, Marc Connell, Anirban Ganguly, Kang Jun Cho, Tatum Tarin, Rajiv Dhir, Biatta Sholosh and Jodi Maranchie
Curr. Oncol. 2023, 30(5), 4632-4647; https://doi.org/10.3390/curroncol30050350 - 30 Apr 2023
Cited by 6 | Viewed by 2668
Abstract
This review article gives an overview of the current state of the art of bladder cancer imaging and then discusses in depth the scientific and technical merit of a novel imaging approach, tracing its evolution from murine cancer models to cancer patients. While [...] Read more.
This review article gives an overview of the current state of the art of bladder cancer imaging and then discusses in depth the scientific and technical merit of a novel imaging approach, tracing its evolution from murine cancer models to cancer patients. While the poor resolution of soft tissue obtained by widely available imaging options such as abdominal sonography and radiation-based CT leaves them only suitable for measuring the gross tumor volume and bladder wall thickening, dynamic contrast-enhanced magnetic resolution imaging (DCE MRI) is demonstrably superior in resolving muscle invasion. However, major barriers still exist in its adoption. Instead of injection for DCE-MRI, intravesical contrast-enhanced MRI (ICE-MRI) instills Gadolinium chelate (Gadobutrol) together with trace amounts of superparamagnetic agents for measurement of tumor volume, depth, and aggressiveness. ICE-MRI leverages leaky tight junctions to accelerate passive paracellular diffusion of Gadobutrol (604.71 Daltons) by treading the paracellular ingress pathway of fluorescein sodium and of mitomycin (<400 Daltons) into bladder tumor. The soaring cost of diagnosis and care of bladder cancer could be mitigated by reducing the use of expensive operating room resources with a potential non-surgical imaging option for cancer surveillance, thereby reducing over-diagnosis and over-treatment and increasing organ preservation. Full article
(This article belongs to the Special Issue Advances and Perspectives in Diagnosis and Treatment Strategies for Bladder Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop